Børsmeldinger | Aqua Bio Technology ASA

Correction: Aqua Bio Technology: Notice of extraordinary general meeting3.7.2025 09:33:41 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

An extraordinary general meeting of Aqua Bio Technology ASA (the "Company" or "ABTEC") will be held on 25 July 2025 at 11:00 (CET) at ABT´s office in Bygdøy Alle 3, Oslo. Please find attached the notice to the general meeting. All documents to be treated at the meeting will be made available at the Company's website https://aquabiotechnology.com/downloads/ Shareholders who wish to the attend the general meeting is requested to notify the Company as set out in Appendix 2 to the notice within 23 July 2025 at 16:00 (CET). In case of attendance by proxy, the proxy form (also included in appendix 2 to the notice) is requested submitted to be received by the Company within the same date.

2 vedlegg

Aqua Bio Technology: Notice of extraordinary general meeting3.7.2025 09:01:35 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

An extraordinary general meeting of Aqua Bio Technology ASA (the "Company" or "ABTEC") will be held on 25 July 2025 at 11:00 (CET) at ABT´s office in Bygdøy Alle 3, Oslo. Please find attached the notice to the general meeting. All documents to be treated at the meeting will be made available at the Company's website www.aquabiotechnology.com - http://www.aquabiotechnology.com - http://www.aquabiotechnology.com. Shareholders who wish to the attend the general meeting is requested to notify the Company as set out in Appendix 2 to the notice within 23 July 2025 at 16:00 (CET). In case of attendance by proxy, the proxy form (also included in appendix 2 to the notice) is requested submitted to be received by the Company within the same date.

2 vedlegg

Aqua Bio Technology ASA – CEO og CFO30.6.2025 08:00:00 CEST | Aqua Bio Technology ASA | Annen informasjonspliktig regulatorisk informasjon

Aqua Bio Technology ASA har engasjert Kristian Flaten som administrerende direktør (CEO) fra 1.august 2025. Kristian vil inntil videre også fungere som selskapets finansdirektør (CFO). Kristian har over 25 års erfaring fra finans og næringsliv, inkludert ledelse, finansiering, corporate governance og forretningsutvikling fra børsnoterte vekstselskaper og internasjonale selskaper. Kristian har tidligere erfaring som CFO fra IDEX Biometrics ASA og Quantafuel ASA, og har ytterligere bakgrunn fra blant annet BW Offshore, Eksportkreditt (Eksfin) og Handelsbanken. Kristian er siviløkonom fra NHH (Norges Handelshøyskole). Styret i Aqua Bio Technology har tidligere annonsert at selskapet går inn i en fase med nye prioriteringer og kostnadsjusteringer. Styret vil presentere dette i løpet av andre halvår 2025.

2 vedlegg

Avholdt ordinær generalforsamling i Aqua Bio Technology ASA25.6.2025 14:49:48 CEST | Aqua Bio Technology ASA | Annen informasjonspliktig regulatorisk informasjon

Det ble i dag avhold ordinær generalforsamling i Aqua Bio Technology ASA i selskapets lokaler. Alle vedtak ble fattet i samsvar med forslagene som fremgår av innkallingen til generalforsamlingen, med unntak av punkt 9: Valg av revisor som vil behandles i kommende ekstraordinær generalforsamling. Protokollen fra generalforsamlingen er vedlagt denne meldingen.

2 vedlegg

AQUA BIO TECHNOLOGY ASA – UPDATE ON SHARE CAPITAL CHANGES AND AUDITOR18.6.2025 08:43:58 CEST | Aqua Bio Technology ASA | Total number of voting rights and capital

Reference is made to extraordinary general meeting of Aqua Bio Technology ASA ("ABT" or the "Company") held on 9 April 2025 (the "EGM"), where it was resolved to carry out, among other things; (i) a share capital decrease through reduction of the par value of the shares in the Company to NOK 0.50 (the "Share Capital Decrease"), (ii) a share capital increase in connection with the private placement announced as successfully placed on 11 March 2025 (the "Private Placement"), and (iii) a share capital increase in connection with the subsequent offering following the Private Placement (the "Subsequent Offering"). In order to complete the Private Placement and the Subsequent Offering by delivery of new shares in these respective transactions, the par value of the Company's shares must be reduced to at least NOK 0.50 (i.e. the subscription price per share in the Private Placement and the Subsequent Offering), which was intended to be completed through the Share Capital Decrease. Subsequent t

1 vedlegg

AQUA BIO TECHNOLOGY ASA – NOTICE OF ANNUAL GENERAL MEETING5.6.2025 14:19:11 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

The annual general meeting of Aqua Bio Technology ASA (the "Company" or "ABT") will be held on 25 June 2025 at 11:00 (CEST) at Bygdøy Allé 3, 0257 Oslo. The notice of the general meeting, including the board's proposed resolutions, the registration and proxy forms, are attached to this notice. The notice of the general meeting with enclosures and relevant documents for the annual general meeting will be made available on the Company's website. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

2 vedlegg

AQUA BIO TECHNOLOGY ASA (ABTEC) - Ny ordre fra Restorsea LLC3.6.2025 12:37:33 CEST | Aqua Bio Technology ASA | Ikke-informasjonspliktige pressemeldinger

Aqua Bio Technology ASA (ABT) har mottatt en ny ordre fra Restorsea LLC på Aquabeautine XL®. Denne ordren bekrefter det sterke samarbeidet mellom selskapene og den økende etterspørselen etter ABTs unike ingredienser. Aquabeautine XL® er teknologien som opprinnelig ble utviklet av ABT, og de globale rettighetene til denne teknologien ble i sin tid solgt for 25 millioner USD. Disse rettighetene er nå tilbake hos ABT. Salg, utvikling og foredling av Aquabeautine XL®, som var grunnlaget for etableringen av Aqua Bio Technology ASA, vil være et av selskapets viktige satsingsområder fremover. Restorsea LLC har samtidig varslet at de planlegger ytterligere en ordre av Aquabeautine XL® i oktober/november 2025, noe som bidrar til stabil og forutsigbar leveransekapasitet for ABT. Aqua Bio Technology ser frem til fortsatt vekst og videreutvikling av partnerskapet med Restorsea LLC.

1 vedlegg

AQUA BIO TECHNOLOGY ASA (ABTEC) – LOI Signed Between Jetcarrier AS and Hofseth International AS21.5.2025 11:51:49 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Aqua Bio Technology (ABTEC)’s wholly owned subsidiary Jetcarrier AS (Jet) has signed a Letter of Intent (LOI) with Hofseth International AS (HI) for transportation services worth potentially NOK 40–50 million annually. The intention is for Jet to facilitate the shipment of approximately 1,000 containers per year, or 16–22 per week, of frozen fish, primarily to North America. Upon entering into a final agreement, Jet will require 12 months of exclusivity. HI is one of Norway's largest producers and a major international supplier of salmon and processed salmon products.

1 vedlegg

AQUA BIO TECHNOLOGY ASA (ABTEC) - LOI inngått mellom Jetcarrier AS og Hofseth International AS21.5.2025 11:51:31 CEST | Aqua Bio Technology ASA | Annen informasjonspliktig regulatorisk informasjon

Aqua Bio Technology (ABTEC) sitt heleide datterselskap Jetcarrier AS (Jet) har inngått LOI med Hofseth International AS (HI) om frakt for potensielt 40-50 millioner kroner årlig. Som intensjon skal Jet fasilitere frakt av omlag 1.000 containere årlig, eller 16-22 ukentlig, med frossen fisk, primært til Nord-Amerika. Ved inngåelse av endelig avtale vil Jet kreve 12 måneders eksklusivitet. HI er en av Norges største produsent og stor internasjonal leverandør av laks og bearbeidede lakseprodukter.

1 vedlegg

AQUA BIO TECHNOLOGY ASA - Buyback of Subsidiaries20.5.2025 08:33:31 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS. The settlement for the sales consists of 11 million ABT shares and 500,000 in cash. As previously reported, ABTEC has identified significant findings in connection with the audit of the companies now sold, for the fiscal year 2024. As part of the settlement, ABTEC retains litigation competence, should there be grounds for this.

1 vedlegg

AQUA BIO TECHNOLOGY ASA – Tilbakesalg av datterselskaper20.5.2025 08:33:01 CEST | Aqua Bio Technology ASA | Annen informasjonspliktig regulatorisk informasjon

Aqua Bio Technology ASA (ABTEC) har inngått avtale med Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS og Hartmanns Norge AS om salg av Ovalen AS, 3D Innovation Nordic AS og Coverbrands AS. Oppgjør for salgene er 11 millioner ABT-aksjer og 500.000 i kontanter. Som tidligere meldt har ABTEC identifisert betydelige funn i forbindelse med revidering av selskapene som nå er solgt, for regnskapsåret 2024. Som en del av oppgjøret beholder ABTEC søksmålskompetanse, dersom det skulle vise seg å være grunnlag for dette.

1 vedlegg

Aqua Bio Technology ASA – 2024 AUDITED ESEF FINANCIAL REPORT15.5.2025 12:49:38 CEST | Aqua Bio Technology ASA | Annual financial and audit reports

For year end 2024 under the Norwegian Securities Trading Act we have attached the Independent Practitioner's Reasonable Assurance Report Relating to the European Single Electronic Format Requirements (“ESEF Regulation”).

3 vedlegg

Aqua Bio Technology ASA - CEO and interim CFO have announced their resignations8.5.2025 21:44:54 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Aqua Bio Technology ASA ('ABTEC' or 'the Company') informs that the CEO and interim CFO have notified the board of their resignations. The decision is based on significantly changed financial conditions of the company and management needs. The CEO and CFO have concluded that a managerial renewal would be appropriate in light of the phase the company is entering, where new priorities and cost adjustments are necessary. The board will restructure the management in accordance with these changes. For further information, please contact:

1 vedlegg

Aqua Bio Technology ASA – CEO og interim CFO har meddelt sin avgang8.5.2025 21:44:42 CEST | Aqua Bio Technology ASA | Annen informasjonspliktig regulatorisk informasjon

Aqua Bio Technology ASA (“ABTEC” eller “Selskapet”) informerer om at administrerende direktør og interim finansdirektør har meddelt styret at de fratrer sine stillinger. Avgjørelsen er begrunnet i selskapets vesentlig endrede finansielle forutsetninger og ledelsesbehov. CEO og CFO har kommet til at en ledelsesmessig fornyelse vil være hensiktsmessig i lys av den fasen selskapet nå går inn i, der nye prioriteringer og kostnadstilpasninger blir nødvendige. Styret vil endre ledelsesstrukturen i tråd med endringene. For ytterligere informasjon, vennligst kontakt:

1 vedlegg

Aqua Bio Technology ASA - Offentliggjøring av årsrapport for 20241.5.2025 08:00:00 CEST | Aqua Bio Technology ASA | Årsrapporter og revisjonsberetninger

Aqua Bio Technology ASA ("ABTEC" og sammen med sine datterselskaper, "Konsernet") offentliggjør i dag konsernets årsrapport for regnskapsåret 2024. Vesentlige finansielle nøkkeltall (konsern): Driftsinntekter: 107,2 millioner kroner (2023: 18,7 millioner kroner) EBITDA: -313,9 millioner kroner (2023: -12,1 millioner kroner) Driftsresultat (EBIT): -325,7 millioner kroner (2023: -15,8 millioner kroner) Årsresultat: -337,4 millioner kroner (2023: -21,0 millioner kroner) Kontantstrøm fra driften: -46,9 millioner kroner (2023: -19,3 millioner kroner) Resultatet for året er i stor grad påvirket av nedskrivninger i konsernets balanse. Det er regnskapsført et tap på 44,7 millioner kroner knyttet til konkurs i et datterselskap, samt foretatt nedskrivninger av andre datterselskaper med til sammen 163,7 millioner kroner Finansiell stilling per 31.12.2024: Totale eiendeler: 249,7 millioner kroner (2023: 237,7 millioner kroner) Kontantbeholdning: 17,2 millioner kroner (2023: 4,8 millioner kroner) E

2 vedlegg

Aqua Bio Technology ASA – Publication of the 2024 Annual Report1.5.2025 08:00:00 CEST | Aqua Bio Technology ASA | Annual financial and audit reports

Aqua Bio Technology ASA (“ABTEC” and, together with its subsidiaries, “the Group”) today publishes the Group’s annual report for the financial year 2024. Key Financial Highlights (Group): Operating revenues: NOK 107.2 million (2023: NOK 18.7 million) EBITDA: NOK -313.9 million (2023: NOK -12.1 million) Operating result (EBIT): NOK -325.7 million (2023: NOK -15.8 million) Net result: NOK -337.4 million (2023: NOK -21.0 million) Cash flow from operations: NOK -46.9 million (2023: NOK -19.3 million) The result for the year was significantly impacted by impairments in the Group’s balance sheet. An accounting loss of NOK 44.7 million was recognized due to the bankruptcy of a subsidiary, in addition to impairments of other subsidiaries amounting to NOK 163.7 million. Financial Position as of 31.12.2024: Total assets: NOK 249.7 million (2023: NOK 237.7 million) Cash balance: NOK 17.2 million (2023: NOK 4.8 million) Equity: NOK -81.7 million (2023: positive) Equity ratio: -32.7% (2023: positiv

2 vedlegg

AQUA BIO TECHNOLOGY ASA – The Board of ABTEC ASA Informs the Market About Significant Findings in the 2024 Audit Process28.4.2025 08:56:24 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

The Board of Aqua Bio Technology ASA ("ABTEC" or "the Company") informs that in connection with the audit process for the fiscal year 2024, issues have been identified in three of the Company's subsidiaries: Coverbrands AS, 3D Innovation Nordic AS, and Ovalen AS. Transactions with related parties have been identified that, as of today, do not appear to be sufficiently documented or commercially justified. These issues may have an impact on the assessment of certain income and balance sheet items in the consolidated financial statements, and the Board currently does not have sufficient information to make a determination. The Company's group auditor has informed the Board that no conclusion for the consolidated financial statements can be made as long as the documentation and information on the above-mentioned transactions stand. The Board has initiated a process to review the matters in collaboration with external legal and financial advisors. The purpose of the review is to assess the

1 vedlegg

AQUA BIO TECHNOLOGY ASA – Styret i ABT ASA informerer markedet om vesentlige funn i revisjonsprosessen for 202428.4.2025 08:56:10 CEST | Aqua Bio Technology ASA | Annen informasjonspliktig regulatorisk informasjon

Styret i Aqua Bio Technology ASA ("ABTEC" eller "Selskapet") informerer om at det i forbindelse med revisjonsprosessen for regnskapsåret 2024 er avdekket forhold i tre av Selskapets datterselskaper; Coverbrands AS, 3D Innovation Nordic AS og Ovalen AS. Det er identifisert transaksjoner med nærstående parter som per i dag ikke fremstår som tilstrekkelig dokumentert eller forretningsmessig begrunnet. Disse forholdene kan ha betydning for vurderingen av enkelte resultat- og balanse-poster i konsernregnskapet og styret har per i dag ikke tilstrekkelig informasjon til å ta stilling til dette. Selskapets konsernrevisor har orientert styret om at det ikke vil kunne foreligge en konklusjon for konsernregnskapet slik dokumentasjon og informasjon om de ovennevnte transaksjoner står. Styret har iverksatt en prosess for å gjennomgå forholdene i samarbeid med ekstern juridisk og økonomisk rådgiver. Formålet med gjennomgangen er å vurdere forutsetningene for kjøpene av de berørte datterselskapene, n

1 vedlegg

Aqua Bio Technology ASA – Primary Insider Notifications9.4.2025 15:32:18 CEST | Aqua Bio Technology ASA | Mandatory notification of trade primary insiders

Reference is made to the stock exchange notices from Aqua Bio Technology ASA ("ABT" or the "Company") published on 11 March 2025 regarding the successful placement of a private placement of 48,432,000 new shares (the "New Shares") in the Company, at a fixed subscription price of NOK 0.50 per New Share (the "Private Placement"). In an extraordinary general meeting held on 9 April 2025, the share capital increase in connection with the issuance of the New Shares was approved. Completion of the Private Placement by issuance of the New Shares remains subject to, inter alia, valid subscription and settlement of share deposits for all New Shares as well as completion of a share capital decrease resolved in the extraordinary general meeting held on 9 April 2025. The following primary insiders or close associates of primary insiders have been allocated New Shares: Initia AB, a company closely associated with former director Jan Pettersson, has been allocated 500,000 New Shares, for a total sub

2 vedlegg

AQUA BIO TECHNOLOGY ASA – MINUTES FROM EXTRAORDINARY GENERAL MEETING – UPDATE ON FINANCING9.4.2025 13:34:13 CEST | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Aqua Bio Technology ASA ("ABTEC" or the "Company") has today, on 9 April 2025, held an extraordinary general meeting. All resolutions were made in accordance with the proposals of the Company's Board of Directors. The minutes of the extraordinary general meeting are attached to this notice. In connection with the general meeting, the Company has also received a proposal from an investor group for a further equity investment into the Company at the same price per share as in the private placement announced as placed on 11 March 2025. The Company's Board will review and discuss this proposal and provide further information in due course. DISCLOSURE REGULATION For further information, please contact Fredrik Henriksen, CEO, Phone +47 900 20 078. Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional i

2 vedlegg